Biotime did aggressively persue hESC ip, but it's not like they were greedy about it, NOBODY else 5-10 years ago would touch it. Now things are starting to change and Ithink West had guts to chance it and now partners are lining up to host their clinical trials.
This proves that the future of the use of stem cells within the medical industry is NOT just either embryonic or adult(skin). Take for instance autogolous stem cell transfusions, these are safe and proven and used for decades . Stem cell transfusions use PROGENITOR stem cells.
BTW, BTX also has extensive ip on stem cell growth factors which will also be an avenue along with 'off the shelf' progenitors.
Now that its clear cable companies have lost and internet/phone service providers have won AT&T will dominate. Take a look and see T's maximum chart. $60 range in the early 1090's when economy hit bottom.
Good chance within the next five years T shares will pop as economy stumbles. Netflix, Hulu, Amazon and content providers will take a hit while T phone users will grow.
Cancer market is huge, OCX will be one of the first with nano/big-data cancer diagnostic products available this year. Should be very lucrative.
My take is that BTX will sell OCX after they reap profits over the course of 2016. If so the buyot would likely occur just before the release the 2.0 version of PanC. OCX will at that point be $12-20 and the buyout will fetch a share price of $25-$30.
Another subsidiary to ipo by years end, BTX one of the best next-gen biotech investments for 2016.
PanC-DX Will set the standard
I will be very happy if OncoCyte's IPO goes as well as AST's.
Dendritic cancer vaccines, stem cell spine trials for paralysis, three different cancer diagnostic products about to be released in major hospitals....what don't you like about this company!
Thank you Dr. West, will make a nice Christmas present!
Mothership here, 2016 OncoCyte/BTX products/revenues start to hit market. AST cancer vaccine and or spine trials will be in final stages. My advice: buy now before BTX shares are more like $20 range next year.
Good insight, amazing all that has gotten done in eight years with no revenues, just goes to show how much investors and partners believe in this company.
Proof is in the partners:
CORPORATE PARTNERSHIPS & LICENSING
GE Healthcare (December 2014) »
Abcodia Ltd. (September 2014) »
Cancer Research UK (September 2014) »
University of Wisconsin and Louvain University (August 2014) »
Cornell University (May 2014) »
California Institute of Regenerative Medicine (May 2014) »
Jade Therapeutics (September 2013) »
University of California, Los Angeles (April 2013) »
Wistar Institute (January 2012) »
USCN Life Science, Inc. (December 2011) »
Cornell University (September 2011) »
California Institute of Regenerative Medicine (November 2010) »
Teva Pharmaceutical Industries, Ltd. (October 2010) »
Millipore (July 2009) »
Ocata Therapeutics, Inc. (formerly Advanced Cell Technology, Inc.) (July 2008) »
Wisconsin Alumni Research Foundation (January 2008) »
Hospira, Inc. (U.S.) / CJ Health Corporation (December 2006) »
CJ Health Corporation (April 2003) »
Abbott Laboratories, Inc. (April 1997) » Less